Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04195750 · FLOW

Participant flow

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) · Source last updated 2026-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.
    id
    FG000
    title
    Belzutifan
  2. description
    Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.
    id
    FG001
    title
    Everolimus
  3. description
    Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.
    id
    FG002
    title
    Safety Run-In
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        245
      2. group Id
        FG001
        num Subjects
        253
      3. group Id
        FG002
        num Subjects
        5
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        9
      2. group Id
        FG001
        num Subjects
        8
      3. group Id
        FG002
        num Subjects
        0
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        120
      2. group Id
        FG001
        num Subjects
        110
      3. group Id
        FG002
        num Subjects
        4
      type
      Ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        374
      2. group Id
        FG001
        num Subjects
        372
      3. group Id
        FG002
        num Subjects
        9
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        372
      2. group Id
        FG001
        num Subjects
        360
      3. group Id
        FG002
        num Subjects
        9
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        374
      2. group Id
        FG001
        num Subjects
        372
      3. group Id
        FG002
        num Subjects
        9
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Per protocol, the 9 participants enrolled in the Safety Run-In were not randomized and not included in the protocol-specified analyses for any of the outcome measures.
Complete source fields
groups
  1. description
    Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.
    id
    FG000
    title
    Belzutifan
  2. description
    Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.
    id
    FG001
    title
    Everolimus
  3. description
    Non-Randomized participants enrolled into the Safety Run-in received up to 120 mg of belzutifan QD.
    id
    FG002
    title
    Safety Run-In
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        245
      2. group Id
        FG001
        num Subjects
        253
      3. group Id
        FG002
        num Subjects
        5
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        0
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        9
      2. group Id
        FG001
        num Subjects
        8
      3. group Id
        FG002
        num Subjects
        0
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        120
      2. group Id
        FG001
        num Subjects
        110
      3. group Id
        FG002
        num Subjects
        4
      type
      Ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        374
      2. group Id
        FG001
        num Subjects
        372
      3. group Id
        FG002
        num Subjects
        9
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        372
      2. group Id
        FG001
        num Subjects
        360
      3. group Id
        FG002
        num Subjects
        9
      type
      Treated
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        374
      2. group Id
        FG001
        num Subjects
        372
      3. group Id
        FG002
        num Subjects
        9
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Per protocol, the 9 participants enrolled in the Safety Run-In were not randomized and not included in the protocol-specified analyses for any of the outcome measures.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice